Iron overload and glucose metabolism in subjects with β-thalassaemia major: An overview

Current Diabetes Reviews

Volumn 9, Issue 4, 2013, Pages 332-341

  De Sanctis, Vincenzo ^a   Soliman, Ashraf ^b   Yassin, Mohamed ^b  

^a Pediatric and Adolescent Outpatient Clinic   (Italy)

^b HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Thalassaemia major; Detection of iron overload; Hepatitis C; Impaired glucose tolerance; Insulin dependent diabetes; Iron chelation therapy; Iron overload

Indexed keywords

ANTIDIABETIC AGENT; FERRIC ION; FERRITIN; FERROUS ION; FREE RADICAL; FRUCTOSAMINE; HEMOGLOBIN A1C; IRON; IRON CHELATING AGENT; MEMBRANE LIPID; REACTIVE OXYGEN METABOLITE; SODIUM CALCIUM EXCHANGE PROTEIN;

ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD TRANSFUSION; CELL DEATH; CELL FUNCTION; CHELATION THERAPY; CHILDHOOD DISEASE; CHINA; CROSS-SECTIONAL STUDY; DRUG METABOLISM; FERRITIN BLOOD LEVEL; FINLAND; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEPATITIS C; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; IRON ABSORPTION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON OVERLOAD; IRON STORAGE; LIPID PEROXIDATION; MEDICATION COMPLIANCE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RISK FACTOR; THALASSEMIA MAJOR; VENEZUELA;

EID: 84888226250     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811309040005     Document Type: Article

References (108)

1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86: 480-487.
2. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005; 353: 1135-1146.
3. Chu WC, Au WY, Lam WW. MRI of cardiac iron overload. J Magn Reson Imaging. 2012; 36: 1052-1059.
4. Mehrvar A, Azarkeivan A, Faranoush M, et al. Endocrinopathies in patients with transfusion-dependent α-thalassemia. Pediatr Hematol 2008; 25: 187-194.
5. Abdulzahra MS, Al-Hakeim HK, Ridha MM. Study of the effect of iron overload on the function of endocrine glands in male thalassemia patients. Asian J Transfus Sci 2011; 5: 127-131.
6. De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004; 2 (Suppl 2): 249-255.
7. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with thalassaemia major. Pediatr Endocrinol Rev. 2007; 5: 642-648.
8. Soliman AT, elZalabany MM, Ragab M, et al. Spontaneous and GnRH-provoked gonadotropin secretion and testosterone response to human chorionic gonadotropin in adolescent boys with thalassaemia major and delayed puberty. J Trop Pediatr. 2000; 46: 79-85.
9. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998; 30: 191-201.
10. Gabutti V, Piga A. Results of long term chelation therapy. Acta Haematol 1996; 95: 26-36.
11. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol. 2007; 69: 69-85.
12. 2+ channels provide a major pathway for iron entry into cardiomyocytes in ironoverload cardiomyopathy. Nat Med. 2003; 9: 1187-1194.
13. 2+ channel modifiers: possible implications in iron overload. Circ. Res. 1999; 84: 1302-1309.
14. 2+ channel mRNAs. J Mol Cell Cardiol. 1997; 29: 3035-3042.
15. Williams ME, Feldman DH, McCue AF, et al. Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype. Neuron. 1992; 8: 71-84.
16. 2+ channels and protein kinase C. Mol. Endocrinol. 1996; 10: 90-99.
17. Matsushima S, Tor M, Ozaki K, Narama I. Iron lactate-induced osteomalacia in association with osteoblast dynamics. Toxicol Pathol. 2003; 31: 646-654.
18. 2+]independ on external calcium and the activation of L-type voltage-gated calcium channels in a clonal pituitary cell line (AtT-20) of cultured mouse corticotropes. Cell Calcium. 1996; 19: 327-336.
19. 2+ influx in alpha T3-1 gonadotrophs via the cAMP/PKA signaling system. Am J Physiol Endocrinol Metab. 1997; 273: E850-858.
20. Van Goor F, Zivadinovic D, Stojilkovic SS. Differential expression of ionic channels in rat anterior pituitary cells. Mol. Endocrinol. 2001; 15: 1222-1236.
21. Chang W, Pratt SA, Chen T-H, Tu C-L, Mikala G, Schwartz A, Shoback D. Parathyroid cells express dihydropyridine-sensitive cation currents and L-type calcium channel subunits. Am J Physiol Endocrinol Metab. 2001; 281: E 180-189.
22. Cherednichenko G, Zima AV, Feng W, Schaefer S, Blatter LA, Pessah IN. NADH oxidase activity of rat cardiac sarcoplasmic reticulum regulates calcium-induced calcium release. Circ. Res. 2004; 94: 478-486.
23. Goldhaber JI, Qayyum MS. Oxygen free radicals and excitationcontraction coupling. Antioxid Redox Signal. 2000; 2: 55-64.
24. Lacampagne A, Duittoz A, Bolanos P, Peineau N, Argibay JA. Effect of sulfhydryl oxidation on ionic and gating currents associated with L-type calcium channels in isolated guinea-pig ventricular myocytes. Cardiovasc Res. 1995; 30: 799-806.
25. 2+ influx through L-type voltage-dependent calcium channels by hydroxyl radical in mouse cerebral cortical neurons. Brain Res Mol Brain Res. 2001; 92: 12-18.
26. Kuryshev YA, Brittenham GM, Fujioka H, et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes: implications for the arrhythmogenesis of human siderotic heart disease. Circulation. 1999; 100: 675-683.
27. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 2003; 37: 899-909.
28. Argyropoulou MI, Kiortsis DN, Metafratzi Z, Bitsis S, Tsatoulis A, Efremidis SC. Pituitary gland height evaluated by MR in patients with beta-thalassemia major: a marker of pituitary gland function. Neuroradiology. 2001; 43: 1056-1058.
29. Rahier J, Loozen S, Goebbels RM, Abrahem M. The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia. 1987; 30: 5-12.
30. Cario H, Holl RW, Debatin KM, Kohne E. Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatr. 2003; 162: 139-146.
31. Hardingham GE, Chawla S, Cruzalegui FH, Bading H. Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels. Neuron. 1999; 22: 789-798.
32. Magro S, Puzzonia P, Consarino C, et al. Hypothyroidism in patients with thalassaemia syndromes. Acta Haematol 1990; 84: 72-76.
33. De Sanctis V, Atti G, Lucci M, et al. Endocrine assessment of hypogonadism in patients affected by thalassaemia major. Ric Clin Lab. 1980; 10: 663-671.
34. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998; 30: 191-201.
35. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol. 2007; 69: 69-85.
36. Wood JC, Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 2007; 14: 183-190.
37. Storey P, Thompson AA, Carqueville CL, Wood JC, de Freitas RA, Rigsby CK. R2* imaging of transfusional iron burden at 3T and comparison with 1. 5T, J Magn Reson Imaging 2007; 25: 540-547.
38. Clark PR, St. Pierre TG. Quantitative 1/T2 mapping of hepatic iron overload: a single spin echo imaging methodology. Magn Reson Imaging. 2000; 18: 431-438.
39. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000; 343: 327-331.
40. Wood JC. Diagnosis and management of transfusion iron overload: The role of imaging Am J Hematol. 2007; 82(Suppl 12): 1132-1135.
41. Worwood M, Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J. Binding of serum ferritin to concanavalin A: patients with homozygous beta thalassaemia and transfusional iron overload. Br J Haematol 1980; 46: 409-416.
42. Hershko C, Rachmilewitz EA. Mechanism of desferrioxamineinduced iron excretion in thalassaemia. Br J Haematol. 1979; 42: 125-132.
43. Chapman RW, Hussain MA, Gorman A, et al. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload, J Clin Pathol, 1982; 35: 487-491.
44. Birgegard G, Hallgren R, Killander A, Strömberg A, Venge P, Wide L. Serum ferritin during infection. A longitudinal study. Scand J Haematol, 1978; 21: 333-340.
45. Baynes R, Bezwoda W, Bothwell T, Khan Q, Mansoor N. The nonimmune inflammatory response: serial changes in plasma iron, iron binding capacity, lactoferrin, ferritin and C-reactive protein, Scand J Clin Lab Invest, 1986; 46: 695-704.
46. de Virgilis S, Sanna G, Cornacchia G, et al. Serum ferritin, liver iron stores, and liver histology in children with thalassaemia. Arch Dis Child 1980; 55: 43-45.
47. Cohen A, Cohen IJ, Schwartz E. Scurvy and altered iron stores in thalassaemia major. N Engl J Med 1981; 304: 158-160.
48. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971-977.
49. Jacobs EM, Hendriks JC, van Tits BL, et al. Results of an international round robin for the quantification of serum non-transferrinbound iron: Need for defining standardization and a clinically relevant isoform. Anal Biochem 2005; 341: 241-250.
50. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded betathalassemia/HbE patients treated with an oral chelator. Blood 2004; 104: 1504-1510.
51. Villeneuve JP, Bilodeau M, Lepage R, Côté J, Lefebvre M. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol. 1996; 25: 172-177.
52. Emond MJ, Bronner MP, Carlson TH, Lin M, Labbe RF, Kowdley KV. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999; 45: 340-346.
53. Olynyk J, Williams P, Fudge A, Pulbrook S, Kerr R, Mackinnon M, Hall P. Fine-needle aspiration biopsy for the measurement of hepatic iron concentration. Hepatology. 1992; 15: 502-506.
54. Vermylen C. What is new in iron overload? Eur J Pediatr 2008; 167: 377-381.
55. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood. 2009; 114: 4021-4026.
56. Au WY, Lam WW, Chu W, Tam S, Wong WK, Liang R, Ha SY. A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematologica. 2008; 93: 116-119.
57. de Assis RA, Ribeiro AA, Kay FU, et al. Pancreatic iron storse assessed by magnetic resonance imaging (MRI) in beta thalassemic patients. Eur J Radiol. 2012; 81: 1465-1470.
58. Hoffbrand AV, Wonke B. Iron chelation therapy. J Intern Med Suppl. 1997; 740: 37-41.
59. Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. Comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin. 2006; 30: 329-347.
60. Hoffbrand AV, Wonke B. Deferiprone in iron overload. N Engl J Med. 1995; 333: 598-599.
61. th International Conference on Thalassaemia and the Haemoglobinopathies. Bangkok, Thailand, 31 May-4 June 1999: 0018A.
62. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998; 103: 361-364.
63. Grady R BV, Rachmielewitz EA, Giardina PJ. Optimising chelation therapy: Combining deferiprone and deferoxamine. Blood. 2000; 96: 604a.
64. Pepe A, Meloni A, Rossi G, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. J Cardiovasc Magn Reson. 2013; 15: 1. doi: 10. 1186/1532-429X-15-1.
65. Berdoukas V, Farmaki K, Carson S, Wood J, Coates T. Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med. 2012; 3: 119-29.
66. Cappellini MD. Long-term efficacy and safety of deferasirox. Blood Rev. 2008; 22 (Suppl 2): S35-41.
67. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusiondependent anaemia and iron overload. Br J Haematol. 2009; 147: 752-759.
68. Italian Working Group on Endocrine Complications in Nonendocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassemia major. Clin Endocrinol 1995; 42: 581-586.
69. Dehshal MH, Hooghooghi AH, Kebryaeezadeh A, et al. Zinc deficiency aggravates abnormal glucose metabolism in thalassemia major patients. Med Sci Monit. 2007; 13: 235-239.
70. Iancu TC, Ward RJ, Peters TJ. Ultrastructural changes in the pancreas of carbonyl iron-fed rats. J Pediatr Gastroenterol Nutr. 1990; 10: 95-101.
71. Iancu TC. Biological and ultrastructural aspects of iron overload: an overview. Pediatr Pathol. 1990; 10: 281-296.
72. Torres FA, Bonduel M, Sciuccati G, et al. Beta thalassemia major in Argentina. Medicina 2002; 62: 124-134.
73. Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT. Serum ferritin levels and endocrinopathy in medically treated patients with α thalassemia major. Ann Hematol. 2012; 91: 1107-1114.
74. Kidson-Gerber GL, Francis S, Lindeman R. Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic. Med J Aust. 2008; 188: 72-75.
75. Hafez M, Youssry I, El-Hamed FA, Ibrahim A. Abnormal glucose tolerance in beta-thalassemia: assessment of risk factors. Hemoglobin. 2009; 33: 101-108.
76. Gamberini MR, Fortini M, De Sanctis V, Gilli G, Testa. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev. 2004; 2 (Suppl 2): 285-291.
77. Jaruratanasirikul S, Chareonmuang R, Wongcharnchailert M, Laosombat V, Sangsupavanich P, Leetanaporn K. Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy. Eur J Pediatr. 2008; 167: 873-876.
78. Kattamis C, Ladis V, Tsoussis D, Kaloumenou I, Theodoridis C. Evolution of glucose intolerance and diabetes in transfused patients with thalassemia. Pediatr Endocrinol Rev. 2004; 2 (Suppl 2): 267-271.
79. Soltesz G, Patterson CC, Dahlquist G; EURODIAB Study Group. Worldwide childhood type 1 diabetes incidence--what can we learn from epidemiology? Pediatr Diabetes. 2007; 8 (Suppl 6): 6-14.
80. Mowla A, Karimi M, Afrasiabi A, De Sanctis V. Prevalence of diabetes mellitus and impaired glucose tolerance in betathalassemia patients with and without hepatitis C virus infection. Pediatr Endocrinol Rev. 2004; 2 (Suppl 2): 282-284.
81. De Sanctis V, D'Ascola G, Wonke B. The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients. Postgrad Med J 1986; 62: 831-836.
82. Labropoulou KC, Goritsas C, Fragopanagou H, Repandi M, Matsouka P, Alexandrides T. High prevalence of diabetes mellitus among adult beta-thalassaemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1999; 11: 1033-1036.
83. Khalifa AS, Salem M, Mounir E, El-Tawil MM, El-Sawy M, Abd Al-Aziz MM. Abnormal glucose tolerance in Egyptian betathalassemic patients: possible association with genotyping. Pediatr Diabetes. 2004; 5: 126-132.
84. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassemia major. Br J Haematol 2006; 134: 438-44.
85. Heni M, Machann J, Staiger H, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes Metab Res Rev. 2010; 26: 200-2005.
86. Suvarna J, Ingle H, Deshmukh CT Insulin resistance and beta cell function in chronically transfused patients of thalassemia major. Indian Pediatr. 2006; 43: 393-400.
87. Flynn DM, Fairney A, Jackson D, Clayton BE. Hormonal changes in thalassaemia major. Arch Dis Child 1976; 51: 828-836.
88. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993; 77: 478-483.
89. Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS, Pearson HA, Tamborlane WV. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 1988; 318: 809-814.
90. Chern JP, Lin KH, Lu MY, et al. Abnormal glucose tolerance in transfusion-dependent ß-ihalassemic patients. Diabetes Care 2001; 24: 850-854.
91. Soliman AT, el Banna N, alSalmi I, Asfour M. Insulin and glucagon responses to provocation with glucose and arginine in prepubertal children with thalassemia major before and after long-term blood transfusionJ Trop Pediatr. 1996; 42: 291-296.
92. Mangiagli A, Italia S, Campisi S. Glucose tolerance and beta-cell secretion in patients with thalassaemia major. J Pediatr Endocrinol Metab. 1998; 11 (Suppl 3): 985-986.
93. Angelopoulos NG, Zervas A, Livadas S, Adamopoulos I. Reduced insulin secretion in normoglycaemic patients with betathalassaemia major. Diabet Med. 2006; 23: 1327-1331.
94. el Nawawy A, Soliman AT, el Azzouni O, et al. Interleukin-1-beta, tumour necrosis factor-alpha, islet-cell antibody, and insulin secretion in children with thalassemia major on long-term blood transfusion. J Trop Pediatr. 1996; 42: 362-364.
95. Midiri M, Lo Casto A, Sparacia G, et al. MR imaging of pancreatic changes in patients with transfusion-dependent beta-thalassemia major. AJR Am J Roentgenol. 1999; 173: 187-192.
96. Jimmy PSC, Kai HL, Meng YL, Dong TL, Kuo S, Jong DC, Cheng CF. Abnormal glucose tolerance in transfusion dependent α-thalasemc patients. Diabetes Care2001; 24: 850-854.
97. Ladis V, Theodorides C, Palamidou F, et al. Glucose disturbances and regulation with glibenclamide in thalassemia. J Pediatr Endocrinol Metab. 1998; 11 (Suppl 3): 871-878.
98. Dhouib N, Turki Z, Mellouli F, Frissiras S, Berdousi H, Kattamis C. Efficacy of metformin in the treatment of diabetes mellitus complicating thalassemia major. Tunis Med. 2010; 88: 136.
99. Mangiagli A, Campisi S, De Sanctis V, et al. Study Group of the Italian Pediatric and Diabetes Soceity (SIEDP) on Endocrine Complicaionts in Non-Endocrine Disease. Effects of acarbose in patients with beta-thalassaemia major and abnormal glucose homeostasis. Pediatr Endocrinol Rev. 2004; 2 (Suppl 2): 276-278.
100. Atti G, Capra L, de Sanctis V, Vullo C, Bagni B. Beta-cell function assessed by plasma C-peptide evaluation in diabetic thalassaemic patients. Helv Paediatr Acta. 1983; 38: 123-132.
101. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F. Insulin dependent diabetes in thalassemia. Arch Dis Child 1988; 63: 58-62.
102. Mukhtar NA, Bacchetti P, Ayala CE, Melgar J, Christensen S, Maher JJ, Khalili M. Insulin sensitivity and variability in hepatitis C virus infection using direct measurement. Dig Dis Sci. 2013; 58: 1141-1148.
103. Haghpanah S, Davani M, Samadi B, Ashrafi A, Karimi M. Serum lipid profiles in patients with beta-thalassemia major and intermedia in southern Iran. J Res Med Sci. 2010; 15: 150-154.
104. Incorvaia C, Parmeggiani F, Mingrone G, Sebastiani A, De Sanctis V. Prevalence of retinopathy in diabetic thalassaemic patients. J Pediatr Endocrinol Metab. 1998; 11 (Suppl 3): 879-83.
105. Smaldone A. Glycemic control and hemoglobinopathy: when A1C may not be reliable. Diabetes Spectrum 2008; 21: 46-49.
106. Kosecki SM, Rodgers PT, Adams MB. Glycemic monitoring in diabetics with sickle cell plus beta-thalassemia hemoglobinopathy. Ann Pharmacother. 2005; 39: 1557-1560.
107. Pollak Y, Mechlovich D, Amit T, et al. Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism. J Neural Transm. 2013; 120: 37-48.
108. Mechlovich D, Amit T, Mandel SA, Bar-Am O, Bloch K, Vardi P, Youdim MB. The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage. J Pharmacol Exp Ther. 2010; 333: 874-882.